Church & Dwight
This article was originally published in The Rose Sheet
Executive Summary
Firm plans to continue pushing Crest SpinBrush Pro Clean Sonic for the remainder of the fiscal year, C&D CEO Jim Craigie tells investors at the Oppenheimer & Co. Consumer, Gaming, Lodging and Leisure Conference July 14. Brush is "faster than any other type of power brush out there, so fast it will propel water between your teeth to clean your teeth out," Craigie said. "Brushes like that from competitors sell for $30 to $150. We launched a $15 brush [and] it's our No. 2 seller right now in the marketplace." Chief exec indicated that C&D continues to have momentum from its eight "power brands," including SpinBrush and Arm & Hammer. C&D looks forward to launch of new OxiClean products, as well as Trojan Ecstasy condoms and a "condom card" that fits "discreetly in your purse or wallet," Craigie says. Exec notes that C&D has forayed into $1 billion, unbranded sex toy business and is capturing "record" market share
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.